Stockhub

Sensorion SA: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

18 August 2022

  • curprev 02:2602:26, 18 August 2022 >Paris 1,088 bytes +1,088 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural h..."
Retrieved from "https://stockhub.co/research/Sensorion_SA"